Compare Supplements

Standard approved dosing is 140 mg subcutaneously every 2 weeks OR 420 mg subcutaneously once monthly, under a clinician. A prescription drug; this is informational, not a recommendation.

Any time

Subcutaneous prefilled autoinjector (evolocumab)

5–20 mg once daily (up to 40 mg in selected high-risk patients), titrated to LDL/ApoB targets — under a clinician. A prescription drug; not a self-directed supplement regimen.

Any time

Oral tablet (rosuvastatin 5–20 mg)

• Prior serious hypersensitivity reaction to evolocumab
• Use only under clinician direction as part of a lipid-management plan

• Statins
• Ezetimibe

• Active liver disease or unexplained persistent transaminase elevations
• Pregnancy and breastfeeding
• Known hypersensitivity to rosuvastatin

• Cyclosporine
• Gemfibrozil
• Certain antivirals / protease inhibitors